Role of various proteases in cardiac remodeling and progression of heart failure

Dupree CS (2010) Primary prevention of heart failure: an update. Curr Opin Cardiol 25:478–483 de Couto G, Ouzounian M, Liu PP (2010) Early detection of myocardial dysfunction and heart failure. Nat Rev Cardiol 7:334–344 Dhalla NS, Dent MR, Tappia PS, Sethi R, Barta J, Goyal RK (2006) Subcellular remodeling as a viable target for the treatment of congestive heart failure. J Cardiovasc Pharmacol Ther 11:31–45 Dhalla NS, Saini-Chohan HK, Rodriguez-Leyva D, Elimban V, Dent MR, Tappia PS (2009) Subcellular remodeling may induce cardiac dysfunction in congestive heart failure. Cardiovasc Res 81:429–438 Singh RB, Dandekar SP, Elimban V, Gupta SK, Dhalla NS (2004) Role of proteases in the pathophysiology of cardiac disease. Mol Cell Biochem 263:241–256 Wilson EM, Spinale FG (2001) Myocardial remodeling and matrix metalloproteinases in heart failure: turmoil within the interstitium. Ann Med 33:623–634 Rodríguez D, Morrison CJ, Overall CM (2010) Matrix metalloproteinases: what do they not do? New substrates and biological roles identified by murine models and proteomics. Biochim Biophys Acta 1803:39–54 Cuervo AM, Wong ES, Martinez-Vicente M (2010) Protein degradation, aggregation, and misfolding. Mov Disord 25(Suppl 1):S49–S54 Willis MS, Schisler JC, Portbury AL, Patterson C (2009) Build it up-tear it down: protein quality control in the cardiac sarcomere. Cardiovasc Res 81:439–448 Ali MA, Shulz R (2009) Activation of MMP-2 as a key event in oxidative stress injury to the heart. Front Biosc 14:699–716 Kandasamy AD, Chow AK, Ali MA, Shulz R (2010) Matrix metalloproteinase-2 and myocardial oxidative stress injury: beyond the matrix. Cardiovasc Res 85:413–423 Spinale FG (2007) Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev 87:1285–1342 López B, González A, Querejeta R, Larman M, Díez J (2006) Alterations in the pattern of collagen deposition may contribute to the deterioration of systolic function in hypertensive patients with heart failure. J Am Coll Cardiol 48:89–96 Huang Y, Wang KK (2001) The calpain family and human disease. Trends Mol Med 7:355–362 Kar P, Samanta K, Shaikh S, Chowdhury A, Chakraborti T, Chakraborti S (2010) Mitochondrial calpain system: an overview. Arch Biochem Biophys 495:1–7 Perrin BJ, Huttenlocher A (2002) Calpain. Int J Biochem Cell Biol 34:722–725 Suzuki K, Hata S, Kawabata Y, Sorimachi H (2004) Structure, activation, and biology of calpain. Diabetes 53(Suppl 1):S12–S18 Goll DE, Thompson VF, Li H, Wei W, Cong J (2003) The calpain system. Physiol Rev 83:731–801 Reverter D, Sorimachi H, Bode W (2001) The structure of calcium-free human m-calpain: implications for calcium activation and function. Trends Cardiovasc Med 11:222–229 Reiser J, Adair B, Reinheckel T (2010) Specialized roles for cysteine cathepsins in health and disease. J Clin Invest 120:3421–3431 Mort JS, Buttle DJ (1997) Cathepsin B. Int J Biochem Cell Biol 29:715–720 Lutgens SP, Cleutjens KB, Daemen MJ, Heeneman S (2007) Cathepsin cysteine proteases in cardiovascular disease. FASEB J 21:3029–3041 Frohlich ED, Apstein C, Chobanian AV, Devereux RB, Dustan HP, Dzau V, Fauad-Tarazi F, Horan MJ, Marcus M, Massie B, Pfeffer MA, Re RN, Roccella EJ, Savage D, Shub C (1992) The heart in hypertension. N Engl J Med 327:998–1008 Rodriguez WE, Tyagi N, Deng AY, Adeagbo A, Joshua IG, Tyagi SC (2008) Congenic expression of tissue inhibitor of metalloproteinase in Dahl-salt sensitive hypertensive rats is associated with reduced LV hypertrophy. Arch Physiol Biochem 114:340–348 Laviades C, Varo N, Fernández J, Mayor G, Gil MJ, Monreal I, Díez J (1998) Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation 98:535–540 Marin F, Roldan V, Climent V, Garcia A, Marco P, Lip GY (2003) Is thrombogenesis in atrial fibrillation related to matrix metalloproteinase-1 and its inhibitor, TIMP-1? Stroke 34:1181–1186 Lindsay MM, Maxwell P, Dunn FG (2002) TIMP-1: a marker of left ventricular diastolic dysfunction and fibrosis in hypertension. Hypertension 40:136–141 Timms PM, Wright A, Maxwell P, Campbell S, Dawnay AB, Srikanthan V (2002) Plasma tissue inhibitor of metalloproteinase-1 levels are elevated in essential hypertension and related to left ventricular hypertrophy. Am J Hypertens 15:269–272 Li-Saw-Hee FL, Edmunds E, Blann AD, Beevers LD, Lip GY (2000) Matrix metalloproteinase-9 and tissue inhibitor metalloproteinase-1 levels in essential hypertension. Relationship to left ventricular mass and antihypertensive therapy. Int J Cardiol 75:43–47 Lopez B, Gonzalez A, Diez J (2004) Role of matrix metalloproteinases in hypertension-associated cardiac fibrosis. Curr Opin Nephrol Hypertens 13:197–204 Sakata Y, Yamamoto K, Mano T, Nishikawa N, Yoshida J, Hori M, Miwa T, Masuyama T (2004) Activation of matrix metalloproteinases precedes left ventricular remodeling in hypertensive heart failure rats. Its inhibition as a primary effect of angiotensin-converting enzyme inhibitor. Circulation 109:2143–2149 Cicilini MA, Resende MM, Bissoli NS, Vasquez EC, Cabral AM (1995) Calpain activity of hypertrophic hearts from hypertensive rats. Braz J Med Biol Res 28:621–625 Cheng XW, Obata K, Kuzuya M, Izawa H, Nakamura K, Asai E, Nagasaki T, Saka M, Kimata T, Noda A, Nagata K, Jin H, Shi GP, Iguchi A, Murohara T, Yokota M (2006) Elastolytic cathepsin induction/activation system exists in myocardium and is upregulated in hypertensive heart failure. Hypertension 48:979–987 Díez J (2010) Altered degradation of extracellular matrix in myocardial remodeling: the growing role of cathepsins and cystatins. Cardiovasc Res 87:591–592 Kang PM, Izumo S (2003) Apoptosis in heart: basic mechanisms and implications in cardiovascular diseases. Trends Mol Med 9:177–182 Adams JW, Sakata Y, Davis MG, Sah VP, Wang Y, Liggett SB, Chien KR, Brown JH, Dorn GW II (1998) Enhanced Gαq signaling: a common pathway mediates cardiac hypertrophy and apoptotic heart failure. Proc Natl Acad Sci USA 95:10140–10145 Charlemagne D, Orlowski J, Oliviero P, Rannou F, Saint Beuve C, Swynghedauw B, Lane LK (1994) Alteration of Na, K-ATPase subunit mRNA and protein levels in hypertrophied rat heart. J Biol Chem 269:1541–1547 Liu CP, Yeh JL, Wu BN, Chai CY, Chen IJ, Lai WT (2011) KMUP-3 attenuates ventricular remodeling after myocardial infarction through eNOS enhancement and restoration of MMP-9/TIMP-1 balance. Br J Pharmacol 162:126–135 Koskivirta I, Kassiri Z, Rahkonen O (2010) Mice with tissue inhibitor of metalloproteinase 4 (TIMP4) deletions succumb to induced myocardial infarction but not to cardiac pressure overload. J Biol Chem 285:24487–24493 Franz M, Berndt A, Altendorf-Hofmann A (2009) Serum levels of large tenascin-C varients, matrix metalloproteinase-9, and tissue inhibitors of matrix metalloproteinases in concentric versus eccentric left ventricular hypertrophy. Eur J Heart Fail 11:1057–1062 McGowan BS, Scott CB, Mu A, McCormick RJ, Thomas DP, Margulies KB (2003) Unloading-induced remodeling in the normal and hypertrophic left ventricle. Am J Physiol Heart Circ Physiol 284:H2061–H2068 Xu R, Lin F, Zhang S, Chen X, Hu S, Zheng Z (2010) Signal pathways involved in reverse remodeling of the hypertrophied rat heart after pressure unloading. Int J Cardiol 143:414–423 Vianello A, Caponi L, Franzoni F (2009) Role of matrix metalloproteinases and their tissue inhibitors as potential biomarkers of left ventricular remodeling in the athlete’s heart. Clin Sci (Lond) 117:157–164 Roldán V, Marín F, Gimeno JR, Ruiz-Espejo F, González J, Feliu E, García-Honrubia A, Saura D, de la Morena G, Valdés M, Vincente V (2008) Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy. Am Heart J 156:85–91 Mani SK, Shiraishi H, Balasubramanian S, Yamane K, Chellaiah M, Cooper G, Banik N, Zile, Kuppuswamy D (2008) In vivo administration of calpeptin attenuates calpain activation and cardiomyocyte loss in pressure-overloaded feline myocardium. Am J Physiol Heart Circ Physiol 295:H314–H326 Letavernier E, Perez J, Bellocq A, Mesnard L, de Castro Keller A, Haymann JP, Baud L (2008) Targeting the calpain/calpastatin system as a new strategy to prevent cardiovascular remodeling in angiotensin II-induced hypertension. Circ Res 102:720–728 Arthur GD, Belcastro AN (1997) A calcium stimulated cysteine protease involved in isoproternol induced cardiac hypertrophy. Mol Cell Biochem 176:241–248 Schönberger J, Seidman CE (2001) Many roads lead to a broken heart: the genetics of dilated cardiomyopathy. Am J Hum Genet 69:249–260 Matsumoto Y, Tsukada Y, Miyakoshi A, Sakuma H, Kohyama K (2004) C protein-induced myocarditis and subsequent dilated cardiomyopathy: rescue from death and prevention of dilated cardiomyopathy by chemokine receptor DNA therapy. J Immunol 173:3535–3541 Matsumoto Y, Park IK, Kohyama K (2009) Matrix metalloproteinase (MMP)-9, but not MMP-2, is involved in the development and progression of C protein-induced myocarditis and subsequent dilated cardiomyopathy. J Immunol 183:4773–4781 Givvimani S, Tyagi N, Sen U, Mishra PK, Qipshidze N, Munjal C, Vacek JC, Abe OA, Tyagi SC (2010) MMP-2/TIMP-2/TIMP-4 versus MMP-9/TIMP-3 in transition from compensatory hypertrophy and angiogenesis to decompensatory heart failure. Arch Physiol Biochem 116:63–72 Thomas CV, Coker ML, Zellner JL, Handy JR, Crumbley AJ III, Spinale FG (1998) Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation 97:1708–1715 Spinale FG, Coker ML, Heung LJ, Bond BR, Gunasinghe HR, Etoh T, Goldberg AT, Zellner JL, Crumbley AJ (2000) A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation 102:1944–1949 Li YY, Feldman AM, Sun Y, McTiernan CF (1998) Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. Circulation 98:1728–1734 Sivakumar P, Gupta S, Sarkar S, Sen S (2008) Upregulation of lysyl oxidase and MMPs during cardiac remodeling in human dilated cardiomyopathy. Mol Cell Biochem 307:159–167 Ohtsuka T, Nishimura K, Kurata A, Ogimoto A, Okayama H, Higaki J (2007) Serum matrix metalloproteinase-3 as a novel marker for risk stratification of patients with nonischemic dilated cardiomyopathy. J Card Fail 13:752–758 Tang LJ, Chen XF, Zhu M, Jiang JJ, Lu XB, Du YX, Wang B, Fang CF, Xue YS, Shen WF (2007) Matrix metalloproteinase-1, -3, -9 gene polymorphisms and the risk of idiopathic dilated cardiomyopathy in a Chinese Han population. Clin Biochem 40:1427–1430 Amalinei C, Caruntu ID, Balan RA (2007) Biology of metalloproteinases. Rom J Morphol Embryol 48:323–334 Spruill LS, Lowry AS, Stroud RE, Squires CE, Mains IM, Flack EC, Beck C, Ikonomidis JS, Crumbley AJ, McDermott PJ, Spinale FG (2007) Membrane-type-1 matrix metalloproteinase transcription and translation in myocardial fibroblasts from patients with normal left ventricular function and from patients with cardiomyopathy. Am J Physiol Cell Physiol 293:C1362–C1373 Remacle A, Murphy G, Roghi C (2003) Membrane type I-matrix metalloproteinase (MT1–MMP) is internalized by two different pathways and is recycled to the cell surface. J Cell Sci 116:3905–3916 Stypmann J, Gläser K, Roth W, Tobin DJ, Petermann I, Matthias R, Mönnig G, Haverkamp W, Breithardt G, Schmahl W, Peters C, Reinheckel T (2002) Dilated cardiomyopathy in mice deficient for the lysosomal cysteine peptidase cathepsin L. Proc Natl Acad Sci USA 99:6234–6239 Spira D, Stypmann J, Tobin DJ, Petermann I, Mayer C, Hagemann S, Vasiljeva O, Günther T, Schüle R, Peters C, Reinheckel T (2007) Cell type-specific functions of the lysosomal protease cathepsin L in the heart. J Biol Chem 282:37045–37052 Tang Q, Cai J, Shen D, Bian Z, Yan L, Wang YX, Lan J, Zhuang GQ, Ma WZ, Wang W (2009) Lysosomal cysteine peptidase cathepsin L protects against cardiac hypertrophy through blocking AKT/GSK3beta signaling. J Mol Med 87:249–260 Yu XH, Zhang XG, Li SJ, Wang SJ, Zhao G, Chen RZ, Yang YZ (2005) The expression and significance of myocardial cathepsin L in dilated cardiomyopathy. Zhonghua Nei Ke Za Zhi 44:495–498 Ge J, Zhao G, Chen R, Li S, Wang S, Zhang X, Zhuang Y, Du J, Yu X, Li G, Yang Y (2006) Enhanced myocardial cathepsin B expression in patients with dilated cardiomyopathy. Eur J Heart Fail 8:284–289 Dhalla NS, Liu X, Panagia V, Takeda N (1998) Subcellular remodeling and heart dysfunction in chronic diabetes. Cardiovasc Res 40:239–247 Ahmed SS, Jaferi G, Narang RM, Regan TJ (1975) Preclinical abnormality of left ventricular function in diabetes mellitus. Am Heart J 89:153–158 Factor SM, Minase T, Sonnenblick EH (1980) Clinical and morphological features of human hypertensive–diabetic cardiomyopathy. Am Heart J 99:446–458 Regan TJ (1983) Congestive heart failure in the diabetic. Annu Rev Med 34:161–168 Li Q, Sun SZ, Wang Y, Tian YJ, Liu MH (2007) The roles of MMP-2/TIMP-2 in ECM remodelling in the hearts of STZ-induced diabetic rats. Acta Cardiol 62:485–491 Bollano E, Omerovic E, Svensson H, Waagstein F, Fu M (2007) Cardiac remodeling rather than disturbed myocardial energy metabolism is associated with cardiac dysfunction in diabetic rats. Int J Cardiol 114:195–201 Westermann D, Rutschow S, Jäger S, Linderer A, Anker S, Riad A, Unger T, Schultheiss HP, Pauschinger M, Tschöpe C (2007) Contributions of inflammation and cardiac matrix metalloproteinase activity to cardiac failure in diabetic cardiomyopathy: the role of angiotensin type 1 receptor antagonism. Diabetes 56:641–646 Van Linthout S, Seeland U, Riad A, Eckhardt O, Hohl M, Dhayat N, Richter U, Fischer JW, Böhm M, Pauschinger M, Schultheiss HP, Tschöpe C (2008) Reduced MMP-2 activity contributes to cardiac fibrosis in experimental diabetic cardiomyopathy. Basic Res Cardiol 103:319–327 Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI (1995) Mechanism of cell surface activation of 72 kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem 270:5331–5338 Yagi K, Kim S, Wanibuchi H, Yamashita T, Yamamura Y, Iwao H (1997) Characteristics of diabetes, blood pressure, and cardiac and renal complications in otsuka long-evans Tokushima fatty rats. Hypertension 29:728–735 Tayebjee MH, Lip GY, MacFadyen RJ (2005) What role do ECM changes contribute to the cardiovascular disease burden of diabetes mellitus? Diabet Med 22:1628–1635 Hayashi T, Sohmiya K, Ukimura A, Endoh S, Mori T, Shimomura H, Okabe M, Terasaki F, Kitaura Y (2003) Angiotensin II receptor blockade prevents microangiopathy and preserved diastolic function in the diabetic rat heart. Heart 89:1236–1242 Huang CC, Chuang JH, Chou MH, Wu CL, Chen CM, Wang CC, Chen YS, Chen CL, Tai MH (2005) Matrilysin (MMP-7) is a major matrix metalloproteinase upregulated in biliary atresia-associated liver fibrosis. Mod Pathol 18:941–950 Zuo F, Kaminski N, Eugui E, Allard J, Yakhini Z, Ben-Dor A, Lollini L, Morris D, Kim Y, DeLustro B, Sheppard D, Pardo A, Selman M, Heller RA (2002) Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans. Proc Natl Acad Sci USA 99:6292–6297 Boixel C, Fontaine V, Rücker-Martin C, Milliez P, Louedec L, Michel JB, Jacob MP, Hatem SN (2002) Fibrosis of the left atria during progression of heart failure is associated with increased matrix metalloproteinases in the rat. J Am Coll Cardiol 42:336–344 Ban CR, Twigg SM, Franjic B, Brooks BA, Celermajer D, Yue DK, McLenna SV (2010) Serum MMP-7 is increased in diabetic renal disease and diabetic diastolic dysfunction. Diabetes Res Clin Pract 87:335–341 Li Y, Li Y, Feng Q, Arnold M, Peng T (2009) Calpain activation contributes to hyperglycaemia-induced apoptosis in cardiomyocytes. Cardiovasc Res 84:100–110 Williamson CL, Dabkowski ER, Baseler WA, Croston TL, Alway SE, Hollander JM (2010) Enhanced apoptotic propensity in diabetic cardiac mitochondria: influence of subcellular spatial location. Am J Physiol Heart Circ Physiol 298:H633–H642 Bojunga J, Nowak D, Mitrou PS, Hoelzer D, Zeuzem S, Chow KU (2004) Antioxidative treatment prevents activation of death-receptor- and mitochondrion-dependent apoptosis in the hearts of diabetic rats. Diabetologia 47:2072–2080 Cai L, Li W, Wang G, Guo L, Jiang Y, Kang YJ (2002) Hyperglycemia-induced apoptosis in mouse myocardium: mitochondrial cytochrome C-mediated caspase-3 activation pathway. Diabetes 51:1938–1948 Ghosh S, Pulinilkunnil T, Yuen G, Kewalramani G, An D, Qi D, Abrahani A, Rodrigues B (2005) Cardiomyocyte apoptosis induced by short-term diabetes requires mitochondrial GSH depletion. Am J Physiol Heart Circ Physiol 289:H768–H776 Kuo TH, Giacomelli F, Wiener J (1984) Lysosomal and nonlysosomal proteolytic activities in experimental diabetic cardiomyopathy. Exp Mol Pathol 40:280–287 Urbich C, Dernbach E, Rossig L, Zeiher AM, Dimmeler S (2008) High glucose reduces cathepsin L activity and impairs invasion of circulating progenitor cells. J Mol Cell Cardiol 45:429–436 Takahashi S, Barry AC, Factor SM (1990) Collagen degradation in ischaemic rat hearts. Biochem J 265:233–241 Lerman RH, Apstein CS, Kagan HM, Osmers EL, Chichester CO, Vogel WM, Connelly CM, Steffee WP (1983) Myocardial healing and repair after experimental infarction in the rabbit. Circ Res 53:378–388 Machackova J, Sanganalmath SK, Elimban V, Dhalla NS (2011) Beta-adrenergic blockade attenuates cardiac dysfunction and myofibrillar remodeling in congestive heart failure. J Cell Mol Med 15:545–554 Liu X, Sentex E, Golfman L, Takeda S, Osada M, Dhalla NS (1999) Modification of cardiac subcellular remodeling due to pressure overload by captopril and losartan. Clin Exp Hypertens 21:145–156 Takeo S, Elmoselhi AB, Goel R, Sentex E, Wang J, Dhalla NS (2000) Attenuation of changes in sarcoplasmic reticular gene expression in cardiac hypertrophy by propranolol and verapamil. Mol Cell Biochem 213:111–118 Dhalla NS, Golfman L, Liu X, Sasaki H, Elimban V, Rupp H (1999) Subcellular remodeling and heart dysfunction in cardiac hypertrophy due to pressure overload. Ann NY Acad Sci 874:100–110 Hein S, Scholz D, Fujitani N, Rennollet H, Brand T, Friedl A, Schaper J (1994) Altered expression of titin and contractile proteins in failing human myocardium. J Mol Cell Cardiol 26:1291–1306 Morano I, Hadicke K, Grom S, Koch A, Schwinger RH, Böhm M, Bartel S, Erdmann E, Krause EG (1994) Titin, myosin light chains and C-protein in the developing and failing human heart. J Mol Cell Cardiol 26:361–368 Semb SO, Lunde PK, Holt E, Tonnessen T, Christensen G, Sejersted OM (1998) Reduced myocardial Na+, K+-pump capacity in congestive heart failure following myocardial infarction in rats. J Mol Cell Cardiol 30:1311–1328 Dixon IMC, Hata T, Dhalla NS (1992) Sarcolemmal Na+-K+-ATPase activity in congestive heart failure due to myocardial infarction. Am J Physiol Cell Physiol 262:C664–C671 Shao Q, Ren B, Elimban V, Tappia PS, Takeda N, Dhalla NS (2005) Modification of sarcolemmal Na+-K+ ATPase and Na+/Ca2+ exchanger expression in heart failure by blockade of renin-angiotensin system. Am J Physiol Heart Circ Physiol 288:H2637–H2646 Dixon IMC, Hata T, Dhalla NS (1992) Sarcolemmal calcium transport in congestive heart failure due to myocardial infarction in rats. Am J Physiol Heart Circ Physiol 262:H1387–H1394 Mercadier JJ, Lompre AM, Duc P, Boheler KR, Fraysse JB, Wisenewsky C, Allen PD, Komajda M, Schwartz K (1990) Altered sarcoplasmic reticulum Ca2+-ATPase gene expression in the human ventricle during end-stage heart failure. J Clin Invest 85:305–309 Brillantes AM, Allen P, Takahashi T, Izumo S, Marks AR (1992) Differences in cardiac calcium release channel (ryanodine receptor) expression in myocardium from patients with endstage heart failure caused by ischemic versus dilated cardiomyopathy. Circ Res 71:18–26 Arai M, Alpert NR, MacLennan DH, Barton P, Periasamy M (1993) Alterations in sarcoplasmic reticulum gene expression in human heart failure: a possible mechanism for alterations in systolic and diastolic properties of the failing myocardium. Circ Res 72:463–469 Schwinger RHG, Bohm M, Schmidt U, Karczewski P, Bavendiek U, Flesch M, Krause E, Erdmann E (1995) Unchanged protein levels of SERCA II and phospholamban but reduced Ca2+ uptake and Ca2+ ATPase activity of cardiac sarcoplasmic reticulum from dilated cardiomyopathy patients compared with patients with nonfailing hearts. Circulation 92:3220–3228 Meyer M, Schilinger W, Pieske B, Holubarsch C, Heilmann C, Posival H, Kuwajima G, Mikoshiba K, Just J, Hasenfuss G (1995) Alterations of sarcoplasmic reticulum proteins in failing human dilated cardiomyopathy. Circulation 92:778–784 Coker ML, Thomas CV, Clair MJ, Hendrick JW, Krombach RS, Galis ZS, Spinales FG (1998) Myocardial matrix metalloproteinase activity and abundance with congestive heart failure. Am J Physiol Heart Circ Physiol 274:H1516–H1523 Ducharme A, Frantz S, Aikawa M, Rabkin E, Lindsey M, Rohde LE, Schoen FJ, Kelly RA, Werb Z, Libby P, Lee RT (2000) Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest 106:55–62 Peterson JT, Li H, Dillon L, Bryant JW (2000) Evolution of matrix metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted rat. Cardiovasc Res 46:307–315 Spinale FG, Mukherjee R, Zavadzkas JA, Koval CN, Bouges S, Stroud RE, Dobrucki LW, Sinusas AJ (2010) Cardiac restricted overexpression of membrane type-1 matrix metalloproteinase causes adverse myocardial remodeling following myocardial infarction. J Biol Chem 285:30316–30327 Wagner RD, Delagardelle C, Ernens I, Rouy D, Vaillant M, Beissel J (2006) Matrix metalloproteinase-9 is a marker of heart failure after acute myocardial infarction. J Card Fail 12:66–72 Buralli S, Dini FL, Ballo P, Conti U, Fontanive P, Duranti E, Metelli MR, Marzilli M, Taddei S (2010) Circulating matrix metalloproteinase-3 and metalloproteinase-9 and tissue Doppler measures of diastolic dysfunction to risk stratify patients with systolic heart failure. Am J Cardiol 105:853–856 Yang DC, Ma ST, Tan Y, Chen YH, Li D, Tang B, Chen JS, Su XH, Li G, Zhang X, Yang YJ (2010) Imbalance of matrix metalloproteinases/tissue inhibitor of metalloproteinase-1 and loss of fibronectin expression in patients with congestive heart failure. Cardiology 116:133–141 Hayashidani S, Tsutsui H, Ikeuchi M, Shiomi T, Matsusaka H, Kubota T, Imanaka-Yoshida K, Itoh T, Takeshita A (2003) Targeted deletion of MMP-2 attenuates early LV rupture and late remodeling after experimental myocardial infarction. Am J Physiol Heart Circ Physiol 285:H1229–H1235 van den Borne S, Cleutjens J, Hanemaaijer R, Creemers E, Smits J, Daemen M, Blankesteijn WM (2008) Increased matrix metalloproteinase-8 and -9 activities in patients with infarct rupture after myocardial infarction. Cardiovasc Pathol 18:37–43 Yang D, Ma S, Tan Y, Li D, Tang B, Zhang X, Sun M, Yang Y (2010) Increased expression of calpain and elevated activity of calcineurin in the myocardium of patients with congestive heart failure. Int J Mol Med 26:159–164 Saitoh T, Nakajima T, Takahashi T, Kawahara K (2006) Changes in cardiovascular function on treatment of inhibitors of apoptotic signaling pathways in left ventricular modeling after myocardial infarction. Cardiovasc Pathol 15:130–138 Yoshida H, Takahashi M, Koshimizu M, Tanonaka K, Oikawa R, Toyo-oka T, Takeo S (2003) Decrease in sarcoglycans and dystrophin in failing heart following acute myocardial infarction. Cardiovasc Res 59:419–427 Jin D, Takai S, Sakaguchi M, Okamoto Y, Muramatsu M, Miyazaki M (2004) An antiarrhythmic effect of a chymase inhibitor after myocardial infarction. J Pharmacol Exp Ther 309:490–497 Jahanyar J, Youker KA, Loebe M, Assad-Kottner C, Koerner MM, Torre-Amione G, Noon GP (2007) Mast cell-derived cathepsin g: a possible role in the adverse remodeling of the failing human heart. J Surg Res 140:199–203 Ng LL, Khan SQ, Narayan H, Quinn P, Squire IB, Davies JE (2011) Proteinase 3 and prognosis of patients with acute myocardial infarction. Clin Sci (Lond) 120:231–238 Zidar N, Jera J, Maja J, Dušan Š (2007) Caspases in myocardial infarction. Adv Clin Chem 44:1–33 Chondrogianni N, Gonos ES (2008) Proteasome activation as a novel antiaging strategy. IUBMB Life 60:651–655 Hirano Y, Hendil KB, Yashiroda H, Iemura S, Nagane R, Hioki Y, Natsume T, Tanaka K, Murata S (2005) A heterodimeric complex that promotes the assembly of mammalian 20S proteasomes. Nature 437:1381–1385 Marques AJ, Palanimurugan R, Matias AC, Ramos PC, Dohmen RJ (2009) Catalytic mechanism and assembly of the proteasome. Chem Rev 109:1509–1536 Choudhury S, Bae S, Kumar SR, Ke Q, Yalamarti B, Choi JH, Kirshenbaum LA, Kang PM (2010) Role of AIF in cardiac apoptosis in hypertrophic cardiomyocytes from Dahl salt-sensitive rats. Cardiovasc Res 85:28–37 Park M, Shen YT, Gaussin V, Heyndrickx GR, Bartunek J, Resuello RR, Natividad FF, Kitsis RN, Vatner DE, Vatner SF (2009) Apoptosis predominates in nonmyocytes in heart failure. Am J Physiol Heart Circ Physiol 297:H785–H791 Gottlieb RA, Burleson KO, Kloner RA, Babior BM, Engler RL (1994) Reperfusion injury induces apoptosis in rabbit cardiomyocytes. J Clin Invest 94:1621–1628 Fliss H, Gattinger D (1996) Apoptosis in ischemic and reperfused rat myocardium. Circ Res 79:949–956 Kang PM, Haunstetter A, Aoki H, Usheva A, Izumo S (2000) Morphological and molecular characterization of adult cardiomyocyte apoptosis during hypoxia and reoxygenation. Circ Res 87:118–125 Zhao ZQ, Nakamura M, Wang NP, Wilcox JN, Shearer S, Ronson RS, Guyton RA, Vinten-Johansen J (2000) Reperfusion induces myocardial apoptotic cell death. Cardiovasc Res 45:651–660 Olivetti G, Quaini F, Sala R, Lagrasta C, Corradi D, Bonacina E, Gambert SR, Cigola E, Anversa P (1996) Acute myocardial infarction in humans is associated with activation of programmed myocyte cell death in the surviving portion of the heart. J Mol Cell Cardiol 28:2005–2016 Saraste A, Pulkki K, Kallajoki M, Henriksen K, Parvinen M, Voipio-Pulkki LM (1997) Apoptosis in human acute myocardial infarction. Circulation 95:320–323 Piro FR, di Gioia CR, Gallo P, Giordano C, d’Amati G (2000) Is apoptosis a diagnostic marker of acute myocardial infarction? Arch Pathol Lab Med 124:827–831 Abbate A, Bussani R, Biondi-Zoccai GG, Rossiello R, Silverstri F, Baldi F, Biasucci LM, Baldi A (2002) Persistent infarct-related artery occlusion is associated with an increased myocardial apoptosis at post-mortem examination in humans late after an acute myocardial infarction. Circulation 106:1051–1054 Zidar N, Dolenc-Stražar Z, Jeruc J, Štajer D (2006) Immunohistochemical expression of activated caspase-3 in human myocardial infarction. Virchows Arch 448:75–79 Kostin S, Pool L, Elsässer A, Hein S, Drexler HC, Arnon E, Hayakawa Y, Zimmermann R, Bauer E, Klövekorn WP, Schaper J (2003) Myocytes die by multiple mechanisms in failing human hearts. Circ Res 92:715–724 Communal C, Sumandea M, de Tombe P, Narula J, Solaro RJ, Hajjar RJ (2002) Functional consequences of caspase activation in cardiac myocytes. Proc Natl Acad Sci USA 99:6252–6256 Reeve JLV, Duffy AM, O’Brien T, Samali A (2005) Don’t lose heart: therapeutic value of apoptosis prevention in the treatment of cardiovascular disease. J Cell Mol Med 9:609–622 Date T, Mochizuki S, Belanger AJ, Yamakawa M, Luo Z, Vincent KA, Cheng SH, Gregory RJ, Jiang C (2003) Differential effects of membrane and soluble fas ligand on cardiomyocytes: role in ischemia/reperfusion injury. J Mol Cell Cardiol 35:811–821 Bialik S, Cryns VL, Drincic A, Miyata S, Wollowick AL, Srinivasan A, Kitsis RN (1999) The mitochondrial apoptotic pathway is activated by serum and glucose deprivation in cardiac myocytes. Circ Res 85:403–414 de Moissac D, Gurevich RM, Zheng H, Singal PK, Kirshenbaum LA (2000) Caspase activation and mitochondrial cytochrome c release during hypoxia-mediated apoptosis of adult ventricular myocytes. J Mol Cell Cardiol 32:53–63 Lundberg KC, Szweda LI (2004) Initiation of mitochondrial-mediated apoptosis during cardiac reperfusion. Arch Biochem Biophys 432:50–57 Laugwitz KL, Moretti A, Weig HJ, Gillitzer A, Pinkernell K, Ott T, Pragst I, Städele C, Seyfarth M, Schömig A, Ungerer M (2001) Blocking caspase-activated apoptosis improves contractility in failing myocardium. Hum Gene Ther 12:2051–2063 Hayakawa K, Takemura G, Kanoh M, Li Y, Koda M, Kawase Y, Maruyama R, Okada H, Minatoguchi S, Fujiwara T, Fujiwara H (2003) Inhibition of granulation tissue cell apoptosis during the subacute stage of myocardial infarction improves cardiac remodeling and dysfunction at the chronic stage. Circulation 108:104–109 Yarbrough WM, Mukherjee R, Escobar GP, Sample JA, McLean JE, Dowdy KB, Hendrick JW, Gibson WC, Hardin AE, Mingoia JT, White PC, Stiko A, Armstrong RC, Crawford FA, Spinale FG (2003) Pharmacologic inhibition of intracellular caspases after myocardial infarction attenuates left ventricular remodeling: a potentially novel pathway. J Thorac Cardiovasc Surg 126:1892–1899 Chandrashekhar Y, Sen S, Anway R, Shuros A, Anand I (2004) Long-term caspase inhibition ameliorates apoptosis, reduces myocardial troponin-1 cleavage, protects left ventricular function, and attenuates remodeling in rats with myocardial infarction. J Am Coll Cardiol 43:295–301 Scarabelli TM, Stephanou A, Pasini E, Comini L, Raddino R, Knight RA, Latchman DS (2002) Different signaling pathways induce apoptosis in endothelial cells and cardiac myocytes during ischemia/reperfusion injury. Circ Res 90:745–748 Yaoita H, Ogawa K, Maehara K, Maruyama Y (1998) Attenuation of ischemia/reperfusion injury in rats by a caspase inhibitor. Circulation 97:276–281 Holly TA, Drincic A, Byun Y, Nakamura S, Harris K, Klocke FJ, Cryns VL (1999) Caspase inhibition reduces myocyte cell death induced by myocardial ischemia and reperfusion in vivo. J Mol Cell Cardiol 31:1709–1715 Huang JQ, Radinovic S, Rezaiefar P, Black SC (2000) In vivo myocardial infarct size reduction by a caspase inhibitor administered after the onset of ischemia. Eur J Pharmacol 402:139–142 Mocanu MM, Baxter GF, Yellon DM (2000) Caspase inhibition and limitation of myocardial infarct size: protection against lethal reperfusion injury. Br J Pharmacol 130:197–200 Kovacs P, Bak I, Szendrei L, Vecsernyes M, Varga E, Blasig IE, Tosaki A (2001) Non-specific caspase inhibition reduces infarct size and improves post-ischaemic recovery in isolated ischaemic/reperfused rat hearts. Naunyn Schmiedebergs Arch Pharmacol 364:501–507 Yarbrough WM, Mukherjee R, Stroud RE, Meyer EC, Escobar GP, Sample JA, Hendrick JW, Mingoia JT, Spinale FG (2010) Caspase inhibition modulates left ventricular remodeling following myocardial infarction through cellular and extracellular mechanisms. J Cardiovasc Pharmacol 55:408–416 Sharma AK, Dhingra S, Khaper N, Singal PK (2007) Activation of apoptotic processes during transition from hypertrophy to heart failure in guinea pigs. Am J Physiol Heart Circ Physiol 293:H1384–H1390 Birks EJ, Latif N, Enesa K, Folkvang T, le Luong A, Sarathchandra P, Khan M, Ovaa H, Terracciano CM, Barton PJ, Yacoub MH, Evans PC (2008) Elevated p53 expression is associated with dysregulation of the ubiquitin-proteasome system in dilated cardiomyopathy. Cardiovasc Res 79:472–480 Dent MR, Tappia PS, Dhalla NS (2010) Gender differences in apoptotic signaling in heart failure due to volume overload. Apoptosis 15:499–510 Dent MR, Das S, Dhalla NS (2007) Alterations in both death and survival signals for apoptosis in heart failure due to volume overload. J Mol Cell Cardiol 43:726–732 Powell SR, Divald A (2010) The ubiquitin-proteasome system in myocardial ischaemia and preconditioning. Cardiovasc Res 85:303–311 Willis MS, Patterson C (2006) Into the heart: the emerging role of the ubiquitin-proteasome system. J Mol Cell Cardiol 41:567–579 Song X, von Kampen J, Slaughter CA, DeMartino GN (1997) Relative functions of the alpha and beta subunits of the proteasome activator, PA28. J Biol Chem 272:27994–28000 Zhang Z, Krutchinsky A, Endicott S, Realini C, Rechsteiner M, Standing KG (1999) Proteasome activator 11S REG or PA28: recombinant REG alpha/REG beta hetero-oligomers are heptamers. Biochemistry 38:5651–5658 Ferrington DA, Husom AD, Thompson LV (2005) Altered proteasome structure, function, and oxidation in aged muscle. FASEB J 19:644–646 Husom AD, Peters EA, Kolling EA, Fugere NA, Thompson LV, Ferrington DA (2004) Altered proteasome function and subunit composition in aged muscle. Arch Biochem Biophys 421:67–76 Powell SR, Samuel SM, Wang P, Divald A, Thirunavukkarasu M, Koneru S, Wang X, Maulik N (2008) Upregulation of myocardial 11S-activated proteasome in experimental hyperglycemia. J Mol Cell Cardiol 44:618–621 Churchill EN, Ferreira JC, Brum PC, Szweda LI, Mochly-Rosen D (2010) Ischaemic preconditioning improves proteasomal activity and increases the degradation of deltaPKC during reperfusion. Cardiovasc Res 85:385–394 Powell SR, Wang P, Katzeff H, Shringarpure R, Teoh C, Khaliulin I, Das DK, Davies KJ, Schwalb H (2005) Oxidized and ubiquitinated proteins may predict recovery of postischemic cardiac function: essential role of the proteasome. Antioxid Redox Signal 7:538–546 Yu X, Kem DC (2010) Proteasome inhibition during myocardial infarction. Cardiovasc Res 85:312–320 Ishii T, Sakurai T, Usami H, Uchida K (2005) Oxidative modification of proteasome: identification of an oxidation-sensitive subunit in 26S proteasome. Biochemistry 44:13893–13901 Depre C, Wang Q, Yan L, Hedhli N, Peter P, Chen L, Hong C, Hittinger L, Ghaleh B, Sadoshima J, Vatner DE, Vatner SF, Madura K (2006) Activation of the cardiac proteasome during pressure overload promotes ventricular hypertrophy. Circulation 114:1821–1828 Cardin S, Pelletier P, Libby E, Le Bouter S, Xiao L, Kääb S, Demolombe S, Glass L, Nattel S (2008) Marked differences between atrial and ventricular gene-expression remodeling in dogs with experimental heart failure. J Mol Cell Cardiol 45:821–831 Weekes J, Morrison K, Mullen A, Wait R, Barton P, Dunn M (2003) Hyperubiquitination of proteins in dilated cardiomyopathy. Proteomics 3:208–216 Enrico O, Gabriele B, Nadia C, Sara G, Daniele V, Guilia C, Antonia S, Mario P (2007) Unexpected cardiotoxicity in haematological bortezomib treated patients. Br J Haematol 138:396–397 Hacihanefioglu A, Tarkun P, Gonullu E (2008) Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib. Int J Hematol 88:219–222 Pedrozo Z, Sánchez G, Torrealba N, Valenzuela R, Fernández C, Hidalgo C, Lavendero S, Donoso P (2010) Calpains and proteasomes mediate degradation of ryanodine receptors in a model of cardiac ischemic reperfusion. Biochim Biophys Acta 1802:356–362 Moss NC, Stansfield WE, Willis MS, Tang RH, Selzman CH (2007) IKKbeta inhibition attenuates myocardial injury and dysfunction following acute ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 293:H2248–H2253 Moss NC, Tang RH, Willis M, Stansfield WE, Baldwin AS, Selzman CH (2008) Inhibitory kappa B kinase-beta is a target for specific nuclear factor kappa B-mediated delayed cardioprotection. J Thorac Cardiovasc Surg 136:1274–1279 Campbell B, Adams J, Shin YK, Lefer AM (1999) Cardioprotective effects of a novel proteasome inhibitor following ischemia and reperfusion in the isolated perfused rat heart. J Mol Cell Cardiol 31:467–476 Pye J, Ardeshirpour F, McCain A, Bellinger DA, Merricks E, Adams J, Elliott PJ, Pein C, Fischer TH, Baldwin AS Jr, Nichols TC (2003) Proteasome inhibition ablates activation of NF-kappa B in myocardial reperfusion and reduces reperfusion injury. Am J Physiol Heart Circ Physiol 284:H919–H926 Stansfield WE, Moss NC, Willis MS, Tang R, Selzman CH (2007) Proteasome inhibition attenuates infarct size and preserves cardiac function in a murine model of myocardial ischemia-reperfusion injury. Ann Thorac Surg 84:120–125 Divald A, Powell SR (2006) Proteasome mediates removal of proteins oxidized during myocardial ischemia. Free Radic Biol Med 40:156–164 Meiners S, Dreger H, Fechner M, Bieler S, Rother W, Günther C, Baumann G, Stangl V, Stangl K (2008) Suppression of cardiomyocyte hypertrophy by inhibition of the ubiquitin-proteasome system. Hypertension 51:302–308 Fang CX, Dong F, Thomas DP, Ma H, He L, Ren J (2008) Hypertrophic cardiomyopathy in high-fat diet-induced obesity: role of suppression of forkhead transcription factor and atrophy gene transcription. Am J Physiol Heart Circ Physiol 295:H1206–H1215 Gao Y, Lecker S, Post MJ, Hietaranta AJ, Li J, Volk R, Li M, Sato K, Saluja AK, Steer ML, Goldberg AL, Simons M (2000) Inhibition of ubiquitin-proteasome pathway-mediated IκBα degradation by a naturally occurring antibacterial peptide. J Clin Invest 106:439–448 Hedhli N, Lizano P, Hong C, Fritzky LF, Dhar SK, Liu H, Tian Y, Gao S, Madura K, Vatner SF, Depre C (2008) Proteasome inhibition decreases cardiac remodeling after initiation of pressure overload. Am J Physiol Heart Circ Physiol 295:H1385–H1393 Field ML, Clark JF (1997) Inappropriate ubiquitin conjugation: a proposed mechanism contributing to heart failure. Cardiovasc Res 33:8–12 Norberg E, Gogvadze V, Ott M, Horn M, Uhlén P, Orrenius S, Zhivotovsky B (2008) An increase in intracellular Ca2+ is required for the activation of mitochondrial calpain to release AIF during cell death. Cell Death Differ 12:1857–1864 Cao G, Xing J, Xiao X, Liou AK, Gao Y, Yin XM, Clark RS, Graham SH, Chen J (2007) Critical role of calpain I in mitochondrial release of apoptosis-inducing factor in ischemic neuronal injury. J Neurosci 27:9278–9293 Polster BM, Basanez G, Etxebarria A, Hardwick JM, Nicholls DG (2005) Calpain I induces cleavage and release of apoptosis-inducing factor from isolated mitochondria. J Biol Chem 280:6447–6454